Abstract 4250
Background
The immune system plays a pivotal role in modulating response to monoclonal antibodies therapy in cancer. Novel immune-checkpoint inhibitors have demonstrated potent efficacy alone and in combinations with cytotoxic agents in several cancers. In this regard, avelumab in combination with cetuximab might be a relevant re-challenge strategy in RAS wild type (WT) metastatic colorectal cancer (mCRC) patients treated in first line with chemotherapy (CT) in combination with anti-epidermal growth factor receptor (EGFR) drugs and who achieved a complete or partial response.
Trial design
CAVE Colon is a single arm, multi-center phase II study designed to evaluate the efficacy of avelumab and cetuximab in pre-treated RAS WT mCRC patients. Eligible patients: pathologically confirmed KRAS (exon 2, 3 and 4) and NRAS (exon 2, 3 and 4) WT mCRC treated with a first line CT in combination with an anti-EGFR agent with a major response achieved (complete or partial), who have progressed to a second line therapy, and received no prior immunotherapy. Primary endpoint is overall survival; secondary endpoints are overall response rate according to RECIST 1.1, progression free survival and safety profile. This study seeks to demonstrate a median OS of 11 months by the experimental combination for comparison with historical median OS 8.0 with standard third line treatments, which correspond to an improvement of OS at 6 months from 40% to 57%. With 80% power and 1-sided 5% level test, it was estimated that it would be needed to enrol 66 patients. Considering a potential dropout of approximately 15% of patients, a total of 75 patients will be recruited. The accrual period, started in August 2018, will be 18 months and the total duration of the study will be 36 months. As per April 22nd 2019, thirty-five patients have been enrolled and started the treatment with avelumab 10 mg/kg q14 as a 1-hour i.v. infusion and cetuximab at 400 mg/m2 over 2-hour and subsequently 250 mg/m2 q7 as 1-hour i.v. infusion until disease progression or unacceptable toxicity.
Clinical trial identification
2017-004392-32.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This study is partially supported by Merck KgA, Darmstadt, Germany.
Disclosure
E. Martinelli: Advisory / Consultancy: Amgen, Bayer, Merck, Roche, Sanofi, Servier. T. Troiani: Advisory / Consultancy: Amgen, Bayer, Merck, Novartis, Roche. F. Ciardiello: Advisory / Consultancy: Merck Kga, Bayer, Amgen, Rocher, Servier, Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
1058 - Assessment of CPS+EG, Neo-Bioscore and modified Neo-Bioscore in breast cancer patients treated with preoperative systemic therapy: a multicenter cohort study
Presenter: LING XU
Session: Poster Display session 2
Resources:
Abstract
1156 - The concordance of treatment decision guided by Oncotype and the PREDICT tool in early stage breast cancer
Presenter: Hadar Goldvaser
Session: Poster Display session 2
Resources:
Abstract
3447 - Influence of first treatment delay on survival among breast cancer subtypes
Presenter: Irene Zarcos Pedrinaci
Session: Poster Display session 2
Resources:
Abstract
3505 - Clinical features of early-stage (I-III) triple-negative breast cancer (TNBC) patients with tumors exhibiting low-overall change in molecular profile after neoadjuvant therapy.
Presenter: Nour Abuhadra
Session: Poster Display session 2
Resources:
Abstract
5442 - Meta-analysis in HER2+ early breast cancer therapies and cost-effectiveness in a Brazilian perspective
Presenter: Marcos Magalhaes
Session: Poster Display session 2
Resources:
Abstract
1570 - Anti-mullerian hormone (AMH) levels and antral follicle counts (AFC) may predict ovarian reserves before systemic chemotherapy (SC) in women with breast cancer(BC); a prospective clinical study
Presenter: Cetin Ordu
Session: Poster Display session 2
Resources:
Abstract
2698 - Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy.
Presenter: Giuseppe Cancello
Session: Poster Display session 2
Resources:
Abstract
3104 - Novel Blood Based Circulating Tumor Cell Biomarker For Breast Cancer Detection
Presenter: Chun-Yu Liu
Session: Poster Display session 2
Resources:
Abstract
4631 - Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response of ER-Positive HER2-Negative Breast Cancer Patients to Neo-Adjuvant Chemotherapy
Presenter: Claudia Mazo
Session: Poster Display session 2
Resources:
Abstract
4632 - Impact of menopause status on breast cancer outcomes and amenorrhea incidence during adjuvant tailored dose dense chemotherapy
Presenter: Andri Papakonstantinou
Session: Poster Display session 2
Resources:
Abstract